The minimal underlying data set necessary for replication of this study is available within the paper and its Supporting Information files.

Introduction {#sec006}
============

Apart from bone homeostasis, vitamin D (25(OH)D) has been implicated in an increasing number of physiological mechanisms, including sleep. \[[@pone.0180901.ref001]\] Several studies have identified vitamin D receptors (VDR) in nearly all tissues in the body, including both neuronal and glial cells in the central nervous system. \[[@pone.0180901.ref002]\] VDR are present in multiple areas of the human brain, including the prefrontal cortex, cingulate gyrus, thalamus, substantia nigra, hippocampus, and also the hypothalamus, a brain area that regulates sleep-wake cycle among other behaviors. \[[@pone.0180901.ref002]--[@pone.0180901.ref004]\] Moreover, in the last decade, studies reporting associations between sleep disorders and lower levels of 25(OH)D increased consistently. \[[@pone.0180901.ref005]\], \[[@pone.0180901.ref006]\]

Particularly, obstructive sleep apnea (OSA) shares relevant risk factors with 25(OH)D deficit, such as age, obesity, hypertension, kidney disease\[[@pone.0180901.ref007]\], \[[@pone.0180901.ref008]\] and diabetes. \[[@pone.0180901.ref009]\], \[[@pone.0180901.ref010]\] OSA has also been linked to reduced levels of 25(OH)D, as this sleep disorder leads to sleep fragmentation and daytime sleepiness, which might increase the risk of vitamin D deficiency \[[@pone.0180901.ref010]--[@pone.0180901.ref012]\]. In fact, more recently, Liguori et al. have found that continuous positive airway pressure (CPAP) has an impact on the vitamin D homeostasis of male OSA patients, reinforcing a potential causal relationship in the association between OSA and lower levels of this hormone. \[[@pone.0180901.ref013]\], \[[@pone.0180901.ref014]\] Likewise, subjectively measured short sleep duration has also been associated with lower 25(OH)D levels. \[[@pone.0180901.ref015]\], \[[@pone.0180901.ref016]\] Additionally, recent evidence suggested a relationship between objective short sleep duration (measured by actigraphy) and 25(OH)D deficit. \[[@pone.0180901.ref017]\] In a multi-ethnic study, similar results toward reduced actigraphy-measured sleep duration in those with deficient 25(OH)D were reported. \[[@pone.0180901.ref018]\]

However, taken together with the current evidence, it is still not possible to conclude if there is a confounding or modifying effect of a) reduced sleep duration on the association between OSA and lower 25(OH)D; b) OSA on the relationship between short sleep duration and lower 25(OH)D. Thus, we hypothesized in the current study that both sleep quality and quantity would be able to influence 25(OH)D. Therefore, this study aimed to investigate whether OSA and short sleep duration measured by polysomnography (PSG) are independently associated with the risk of serum 25(OH)D deficiency in an adult sample of Sao Paulo, Brazil.

Methods {#sec007}
=======

Data source {#sec008}
-----------

The current study is part of the ERA project, an observational study conducted in Sao Paulo, Brazil, in which individuals with and without OSA were cross-sectionally assessed to stratify potential socio-demographic, clinical, laboratory and image data associated with OSA.

Population {#sec009}
----------

People from both genders, ≥25 years, residents in the city of São Paulo (latitude -*23*.*533773)*, referred to the Sleep Institute (Sao Paulo, Brazil) over a 24-month period, from 2006 to 2007, and who underwent an overnight full PSG study, were invited to participate in the ERA project. Exclusion criteria were: BMI≥40 kg/m^2^, chronic pulmonary disease based on the spirometric classification, New York Heart Association class III or IV heart failure, unstable angina, atrial fibrillation, uncontrolled hypertension, renal disease, recent hospitalization or severe acute conditions, 25(OH)D replacement, CPAP therapy or any previous surgical procedure targeting OSA. The Ethical Committee of the Universidade Federal de Sao Paulo approved this study (registration number 1546/06), which was conducted according to the ethical standards defined in the 1964 Declaration of Helsinki as well as its subsequent amendments. Written informed consent was obtained from all volunteers.

Measurements {#sec010}
------------

Questionnaires and physical assessments were conducted for the evaluation of socio-demographic and clinical parameters considered as potential confounder variables. Overnight laboratory-based PSG studies were scheduled according to the availability of the volunteers, trying to respect their usual bedtime. Sleep recording was assessed by polysomnographic technologist using a digital system (EMBLA^®^ N7000, Embla Systems Inc., Broomfield, CO, USA). The following physiological tests were performed: electroencephalography (EEG, C3-A2, C4-A1, O1-A2, O2-A1), electrooculography (EOG, EOG-Left-A2, EOG-Right-A1), electromyography (EMG, muscle of the submentonian region, tibialis anterior muscle, and masseter region), electrocardiography (ECG, derivation V1 modified), and airflow detection by both thermocouple and nasal cannula. Respiratory effort was assessed by inductance plethysmography belts, while snoring and body position, percutaneous oxygen saturation (SpO~2~) and pulse rate were evaluated by EMBLA^®^ sensors (Embla Systems Inc., Broomfield, CO, USA). All PSGs were performed and scored by three technicians following guidelines for sleep studies and were reviewed by a sleep medicine physician. All sleep stages were scored according to standardized criteria for investigation of sleep. \[[@pone.0180901.ref019]\] EEG arousals and leg movements were scored according to the criteria established by the American Academy of Sleep Medicine (AASM) Manual for Scoring Sleep and Associated Events. \[[@pone.0180901.ref020]\] Apneas were scored and classified following the recommended rule for adults of the AASM Manual, and hypopneas were scored according to the alternative rule. \[[@pone.0180901.ref020]\]

On the morning following the PSG exam, all participants had a blood sample collected (12 hours of fasting) for quantification of serum levels of total 25(OH)D. After clotting, tubes were centrifuged and kept at −80°C until assayed. We measured serum 25(OH)D using the ARCHITECT 25(OH)D chemiluminescent microparticle immunoassay (Abbott Diagnostics, Wiesbaden, Germany). This method consists of a delayed one-step immunoassay with a six-point calibration for the quantitative measurement of 25(OH)D in a previously described automated instrument system. \[[@pone.0180901.ref021]\]

Statistical analysis {#sec011}
--------------------

Statistical analyses were conducted using Stata 14 (Stata Corp., College Station, Texas, USA). Sample size estimate based on power analysis deriving from previous studies were not carried out as we performed a secondary analysis of the dataset. Descriptive statistics were used to explore the study variables. Serum levels of 25(OH)D below 30 ng/mL were considered as a risk of 25(OH)D deficiency according to the Institute of Medicine of the United States National Academy of Sciences and the US Endocrine Society. \[[@pone.0180901.ref022]\], \[[@pone.0180901.ref023]\] Short sleep duration was considered as PSG-measured total sleep time (TST) lower than 6 hours (360 minutes) while OSA diagnosis was based on an apnea-hypopnea index (AHI) as no OSA (AHI\< 5); mild OSA (5≤AHI\<15), moderate OSA (15≤AHI\<30) and severe OSA (AHI≥30). Other PSG-related variables were sleep efficiency, sleep latency, N1, N2, N3, and REM sleep stages, arousal index (AI), and periodic leg movement index (PLMI).

Based on biological, epidemiological and clinical plausibilities, potential confounders or effect modifiers such as demographics, lifestyle, chronic diseases, and laboratory data were considered in the analyses. Sleep-related variables also tested as potential confounders were categorized: sleep efficiency (\< 80% TST (reduced), ≥ 80% TST (normal)); sleep latency (≥ 30min (increased), \< 30min (normal)); and N1, N2, N3 and REM sleep stages, AI, and PLMI were categorized into quartiles, as a cut-off point for these variables is not clearly established for a wide age range adult population, including older people. \[[@pone.0180901.ref024]\] Simple logistic regression modeling was applied to assess the individual effects of PSG measured parameters on the risk of 25(OH)D deficiency. \[[@pone.0180901.ref025]\] Thereafter, a final multivariate logistic regression model was performed, controlling for potential confounders specified *a priori*: age, gender, self-reported ethnicity (African American/not-African American), smoking (current/non-current), obesity status (obese: body mass index (BMI)≥30 kg/m~2~; non-obese: BMI\<30kg/m^2^), seasonality (winter/non-winter), sedentarism (yes/no), creatinine levels (mg/dL), hypertension (yes/no), and diabetes (yes/no). The final model included the sleep-related variables that were significant in the univariate models. Moreover, due to the inclusion of both middle-aged and older adults, a subgroup analysis applying the same final model but classifying individuals in two age groups (\<50 years and ≥50 years) was performed. Collinearity among the covariates was evaluated. Hosmer-Lemeshow test was used to assess the goodness-of-fit and the c-statistics to evaluate model discrimination. Results were reported as adjusted odds ratios (aOR) and 95% confidence intervals (CI). A p-value\<0.05 was considered statistically significant.

Results {#sec012}
=======

Of the 950 individuals who were screened, 657 were included and 293 presented any exclusion criteria or did not accept to participate in the study. Among the participants, 391 (59.5%) were at risk for serum 25(OH)D deficiency (25(OH)D\<30 ng/mL). Mean age was 52 ± 9.1 years (age range: 28--78 years), and 368 (56%) were women. A higher proportion of women (63.6%), African American (59.4%), current smokers (62.4%), and sedentary individuals (59.5%) were at risk for 25(OH)D deficiency. Obesity (59.3%), hypertension (57.7%), and diabetes (55.7%) were also more frequent among participants at risk for 25(OH)D deficiency. Furthermore, participants at risk for 25(OH)D deficiency were assessed more frequently during the winter time (62%) ([Table 1](#pone.0180901.t001){ref-type="table"}).

10.1371/journal.pone.0180901.t001

###### Participants characteristics by categories of serum 25(OH)D among 657 individuals participating in the ERA study.

![](pone.0180901.t001){#pone.0180901.t001g}

                                                                                                                Serum 25(OH)D categories (ng/mL)   Total Sample   
  ------------------------------------------------------------------------------------------------------------- ---------------------------------- -------------- -------------
  **Baseline sample, n (%)**[\*](#t001fn001){ref-type="table-fn"}                                               391 (59.5)                         266 (40.5)     657
  **Age, y, mean (SD)**                                                                                         52.2 (9.4)                         51.6 (8.8)     52.0 (9.1)
  **Gender (Female), n (%)**[\*](#t001fn001){ref-type="table-fn"}                                               234 (63.6)                         134 (36.4)     368 (56.0)
  **Race/Ethnicity (African American), n (%)**[\*](#t001fn001){ref-type="table-fn"}                             41 (59.4)                          28 (40.5)      69 (10.5)
  **Obesity (BMI≥30)**[\*\*](#t001fn002){ref-type="table-fn"}, **n (%)**[\*](#t001fn001){ref-type="table-fn"}   124 (59.3)                         85 (40.7)      209 (31.8)
  **Current smoking, n (%)**[\*](#t001fn001){ref-type="table-fn"}                                               63 (62.4)                          38 (37.6)      93 (14.2)
  **Hypertension, n (%)**[\*](#t001fn001){ref-type="table-fn"}                                                  157 (57.7)                         115 (42.3)     272 (41.4)
  **Diabetes, n (%)**[\*](#t001fn001){ref-type="table-fn"}                                                      39 (55.7)                          31 (44.3)      70 (10.7)
  **Sedentarism, n (%)**[\*](#t001fn001){ref-type="table-fn"}                                                   238 (59.5)                         162 (40.5)     410 (62.4)
  **Seasonality (winter), n (%)**[\*](#t001fn001){ref-type="table-fn"}                                          98 (62.0)                          60 (38.0)      158 (24.1)
  **Serum creatinin (mg/dL), mean (SD)**                                                                        1.10 (4.6)                         0.90 (0.2)     1.02 (3.5)
  **Sleep latency (min), mean (SD)**                                                                            22.4 (26.3)                        21.9 (25.8)    22.2 (26.1)
  **Sleep efficiency (%), mean (SD)**                                                                           80.1 (14.1)                        79.8 (12.1)    80.0 (13.3)
  **Arousal index (events/hour), mean (SD)**                                                                    17.8 (18.2)                        22.7 (16.6)    21.3 (74.4)
  **Objective short sleep duration (\<6h), n (%)**[\*](#t001fn001){ref-type="table-fn"}                         164 (54.3)                         138 (45.7)     302 (46.0)
  **Obstructive sleep apnea (OSA) categories**                                                                                                                    
  ***No-OSA*, *n (%)***[\*](#t001fn001){ref-type="table-fn"}                                                    129 (66.2)                         66 (33.9)      195 (29.7)
  ***Mild*, *n (%)***[\*](#t001fn001){ref-type="table-fn"}                                                      114 (63.0)                         67 (37.0)      181 (27.6)
  ***Moderate*, *n (%)***[\*](#t001fn001){ref-type="table-fn"}                                                  67 (50.8)                          65 (49.2)      132 (20.1)
  ***Severe*, *n (%)***[\*](#t001fn001){ref-type="table-fn"}                                                    81 (54.4)                          68 (45.6)      149 (22.7)

\* % of total sample size at risk for 25(OH)D deficiency (\<30 ng/mL) (Sample sizes included in each covariate description is not identical to the total sample due to missing values)

\*\*BMI: Body mass index (Kg/m^2^);

Considering each sleep parameter separately as an exposure variable in simple logistic regression models, moderate and severe OSA, objective short sleep duration and AI (3^th^ and 4^th^ quartiles in comparison to the lowest quartile) were associated with the risk of 25(OH) deficiency (moderate OSA: OR for 25(OH)D\<30 = 1.90, 95% CI: 1.21--2.98, p\<0.01; severe OSA: OR for 25(OH)D\<30 = 1.64, 95% CI: 1.06--2.54, p = 0.03; short sleep duration: OR for 25(OH)D\<30 = 1.49, 95% CI: 1.09--2.04, p = 0.01; AI (quartile 3): OR for 25(OH)D\<30 = 1.64, 95%CI: 1.04--2.68, p = 0.03; AI (quartile 4): OR for 25(OH)D\<30 = 1.69, 95%CI: 1.09--2.62, p = 0.02) ([Table 2](#pone.0180901.t002){ref-type="table"}). During the final modeling, collinearity was detected due to the inclusion of arousal index. Therefore, the final multiple logistic regression model, keeping the adjustment for age, gender, race/ethnicity, obesity, smoking, hypertension, diabetes, sedentarism, seasonality and creatinine serum levels, included OSA and objective short sleep duration. In the final analysis, only OSA and objective short sleep duration still showed significant associations with the risk of 25(OH) deficiency (moderate OSA: OR for 25(OH)D\<30 = 2.21, 95% CI: 1.35--3.64, p\<0.01; severe OSA: OR for 25(OH)D\<30 = 1.78, 95% CI: 1.06--3.00, p = 0.03; short sleep duration: OR for 25(OH)D\<30 = 1.61, 95% CI: 1.15--2.26, p = 0.01) ([Table 3](#pone.0180901.t003){ref-type="table"}). The subgroup analysis stratified by age groups (\<50 years and ≥50 years) is showed in [S1](#pone.0180901.s001){ref-type="supplementary-material"} and [S2](#pone.0180901.s002){ref-type="supplementary-material"} Tables. After conducting this additional secondary analysis, only the subgroup ≥50 years maintained the similar results observed in the total sample regarding the risk of 25(OH) deficiency (moderate OSA: OR for 25(OH)D\<30 = 2.40, 95% CI: 1.26--4.54, p\<0.01; severe OSA: OR for 25(OH)D\<30 = 1.94, 95% CI: 0.97--3,86, p = 0.06; short sleep duration: OR for 25(OH)D\<30 = 1.84, 95% CI: 1.17--2.79, p = 0.01).

10.1371/journal.pone.0180901.t002

###### Simple logistic regression analysis of PSG parameters estimating unadjusted odds ratios for the risk of low serum 25(OH)D (\<30 ng/mL compared to ≥30ng/mL).

![](pone.0180901.t002){#pone.0180901.t002g}

                                                                                           OR          95% CI           P value[\*](#t002fn001){ref-type="table-fn"}
  ---------------------------------------------------------------------- ----------------- ----------- ---------------- -------------------------------------------------
  **Sleep efficiency (\< 80%)**[\*\*](#t002fn002){ref-type="table-fn"}                     0.99        0.58--1.71       0.98
  **Sleep latency (≥ 30min)**                                                              0.80        0.56--1.15       0.30
  **N1 (% TST)**                                                                                                        
  ***Quartile 1***                                                       \< 2.37           0.75        0.47--1.17       0.21
  ***Quartile 2***                                                       2.37 to \< 4.55   Reference                    
  ***Quartile 3***                                                       4.55 to \< 7.08   0.85        0.55--1.34       0.49
  ***Quartile 4***                                                       ≥ 7.08            1.15        0.75--1.77       0.53
  **N2 (% TST)**                                                                                                        
  ***Quartile 1***                                                       \< 51.0           1.30        0.82--2.05       0.26
  ***Quartile 2***                                                       51.0 to \< 57.6   Reference                    
  ***Quartile 3***                                                       57.6 to \< 65.5   1.44        0.91--2.27       0.12
  ***Quartile 4***                                                       ≥ 65.5            1.47        0.95--2.28       0.09
  **N3 (% TST)**                                                                                                        
  ***Quartile 1***                                                       \< 12.0           1.44        0.93--2.22       0.10
  ***Quartile 2***                                                       12.0 to \< 17.3   1.20        0.77--1.86       0.42
  ***Quartile 3***                                                       17.3 to \< 23.6   1.30        0.84--2.01       0.24
  ***Quartile 4***                                                       ≥ 23.6            Reference                    
  **REM (% TST)**                                                                                                       
  ***Quartile 1***                                                       \< 13.6           1.23        0.79--1.92       0.35
  ***Quartile 2***                                                       13.6 to \< 18.8   1.53        0.99--2.35       0.06
  ***Quartile 3***                                                       18.8 to \< 22.9   1.40        0.90--0.17       0.13
  ***Quartile 4***                                                       ≥ 22.9            Reference                    
  **Arousal index (number/h TST)**                                                                                      
  ***Quartile 1***                                                       \< 3.36           Reference                    
  ***Quartile 2***                                                       3.36 to \< 9.94   0.95        0.60--1.52       0.84
  ***Quartile 3***                                                       9.94 to \< 26.7   **1.64**    **1.04--2.58**   **0.03**
  ***Quartile 4***                                                       ≥ 26.7            **1.69**    **1.09--2.62**   **0.02**
  **PLMI (number/h TST)**                                                                                               
  ***Quartile 1***                                                       \< 4.3            Reference                    
  ***Quartile 2***                                                       4.3 to \< 7.8     3.40        0.93--12.49      0.07
  ***Quartile 3***                                                       7.8 to \< 21.9    2.35        0.63--8.72       0.20
  ***Quartile 4***                                                       ≥ 21.9            2.34        0.85--6.43       0.10
  **Objective short sleep duration (\<6 h)**                                               **1.49**    **1.09--2.04**   **0.01**[\*](#t002fn001){ref-type="table-fn"}
  **Obstructive sleep apnea**[\*\*\*](#t002fn003){ref-type="table-fn"}   ***Mild***        1.15        0.75--1.75       0.52
                                                                         ***Moderate***    **1.90**    **1.21--2.98**   **\<0.01**[\*](#t002fn001){ref-type="table-fn"}
                                                                         ***Severe***      **1.64**    **1.06--2.54**   **0.03**[\*](#t002fn001){ref-type="table-fn"}

\* *P*-values\<0.05 were considered significant

\*\* Sleep Efficiency: Total Sleep Time (TST)/Time in Bed x 100

\*\*\* No-OSA status was considered as reference

CI: confidence intervals; REM: rapid eye movement; PLMI: periodic limb movement index; TST: total sleep time

10.1371/journal.pone.0180901.t003

###### Multiple logistic regression analysis[\*](#t003fn001){ref-type="table-fn"} estimating adjusted odds ratios for the risk of low serum 25(OH)D (\<30 ng/mL compared to ≥30 ng/mL).

![](pone.0180901.t003){#pone.0180901.t003g}

                                                                                    aOR        95% CI           *P*-value[\*\*](#t003fn002){ref-type="table-fn"}
  --------------------------------------------------------------------------------- ---------- ---------------- ---------------------------------------------------
  **Age**                                                                           0.98       0.96--1.00       0.06[\*\*](#t003fn002){ref-type="table-fn"}
  **Gender (Female)**                                                               0.83       0.58--1.19       0.31
  **Race/Ethnicity (African American)**                                             1.02       0.59--1.74       0.95
  **Sedentarism**                                                                   0.88       0.62--1.25       0.48
  **Current Smoking**                                                               0.70       0.42--1.13       0.14
  **Hypertension**                                                                  1.10       0.75--1.60       0.64
  **Diabetes**                                                                      1.42       0.82--2.46       0.21
  **Obesity (BMI ≥30)**                                                             0.81       0.55--1.19       0.28
  **Seasonality (winter)**                                                          0.88       0.59--1.29       0.51
  **Serum creatinine**                                                              0.96       0.75--1.23       0.74
  **Objective short sleep duration (\< 6h)**                                        **1.61**   **1.15--2.26**   **0.01**[\*\*](#t003fn002){ref-type="table-fn"}
  **Obstructive sleep apnea categories**[\*\*\*](#t003fn003){ref-type="table-fn"}                               
  ***Mild***                                                                        1.11       0.70--1.75       0.65
  ***Moderate***                                                                    **2.21**   **1.35--3.64**   **\<0.01**[\*\*](#t003fn002){ref-type="table-fn"}
  ***Severe***                                                                      **1.78**   **1.06--3.00**   **0.03**[\*\*](#t003fn002){ref-type="table-fn"}

\* Sample size (n = 624) included in the final analysis was not identical to the total sample due to missing values on covariates

\*\* *P*-values\<0.05 were considered significant

\*\*\* No OSA status was considered as reference

aOR: adjusted odds ratios; CI: confidence intervals; BMI: Body mass index (Kg/m^2^)

Discussion {#sec013}
==========

Recently, some studies have suggested that sleep disorders are associated with decreased levels of serum 25(OH)D in different populations \[[@pone.0180901.ref010]\], \[[@pone.0180901.ref015]\]--\[[@pone.0180901.ref018]\]. Our study confirmed this general hypothesis by showing that moderate to severe OSA and PSG-measured short sleep duration are independently associated with the risk of serum 25(OH)D deficiency in a sample including predominantly middle-aged and older participants, after controlling for major potential confounders. A subgroup analysis also showed that these associations persisted only in the participants who were ≥50 years.

Short sleep duration, as well as poor sleep quality and efficiency, have been found more frequently in individuals with lower serum 25(OH)D levels compared to those with sufficient levels. \[[@pone.0180901.ref015]\], \[[@pone.0180901.ref016]\] Several factors may explain this association, among which a hypothetical review has suggested that lower 25(OH)D levels might lead to sleep impairment and daytime sleepiness through the increase of proinflammatory mediators, such as tumor necrosis factor alpha and interleukin-1. \[[@pone.0180901.ref006]\] On the other hand, short sleep duration could also favor 25(OH)D deficiency as insomnia and insufficient sleep are linked to changes in dietary habits and outdoor activity's patterns. \[[@pone.0180901.ref026]\] In fact, as Afro-descendants are more susceptible to 25(OH)D deficiency as well as higher indexes of daytime sleepiness, a possible link between these two factors may exist. \[[@pone.0180901.ref027]\]

Concurrently, OSA has also been related to higher pro-inflammatory markers commonly associated with 25(OH)D deficiency,\[[@pone.0180901.ref028]\] which in turn may increase OSA risk by predisposing individuals to myopathy, tonsillar hypertrophy, and rhinitis, and thus leading to higher chance of upper airway collapse during sleep. \[[@pone.0180901.ref006]\] Otherwise, the recently reported effects of CPAP on 25(OH)D levels in patients with OSA supports the hypothesis that OSA can interfere with the metabolic pathways related to the 25(OH)D synthesis. \[[@pone.0180901.ref013]\], \[[@pone.0180901.ref014]\] As proposed in patients with chronic obstructive pulmonary diseases,\[[@pone.0180901.ref029]\] OSA-related hypoxia is putatively linked to reduced levels of serum 25(OH)D. Therefore, intermittent hypoxemia during sleep may explain at least in part the mechanisms involved in the relationship between OSA and 25(OH)D deficiency. \[[@pone.0180901.ref030]\] Furthermore, 25(OH)D pleiotropic effects may be associated with an extended range of associations between sleep and health outcomes including mortality. \[[@pone.0180901.ref001]\] Sleep curtailment, as well as OSA, have been consistently related to common chronic conditions, such as hypertension, diabetes, obesity and cardiovascular diseases. \[[@pone.0180901.ref031]\], \[[@pone.0180901.ref032]\] Similarly, 25(OH)D deficiency has also been linked to the development of these comorbidities. \[[@pone.0180901.ref001]\] Therefore, a possible explanation for the existing association of sleep-related parameters or disorders with cardiometabolic outcomes could be due partially to 25(OH)D deficiency.

Interestingly, after stratifying the analysis according to age range, the associations observed in the total sample were only detected in the subgroup with ≥50 years. Although this result derives from a secondary analysis, the increasing relevance of both vitamin D deficiency and sleep disorders in the older population may explain this finding. Indeed, epidemiological studies have found a higher prevalence of vitamin D deficiency among older adults. \[[@pone.0180901.ref033]\], \[[@pone.0180901.ref034]\] Additionally, evidence suggests an age-related decline in VDR expression and 1,25-dihydroxycholecalciferol (1,25(OH)D) activity in some body tissues. \[[@pone.0180901.ref035]\] The impact of this physiological change in the brain needs further investigation. On the other hand, sleep disorders and circadian rhythm deregulation are also more common among older people compared to adults. \[[@pone.0180901.ref036]\] Aging is one of the main risk factors for OSA, and sleep curtailment is more observed in the elderly. \[[@pone.0180901.ref024]\], \[[@pone.0180901.ref037]\] Therefore, OSA and shorter sleep duration in older adults may explain, at least in part, the age-changes in vitamin D levels and metabolism. Furthermore, another possible explanation for the increasing prevalence of sleep disorders in older adults can derive from studies targeting the vitamin D metabolism. However, new studies are necessary to test theses hypotheses.

This is an observational study that cross-sectionally evaluated the association between objectively measured sleep parameters, demographic, and clinical factors with serum 25(OH)D levels. By using a relatively large sample size and controlling the analyses for the most common and important potential confounders in the associations between the risk of 25(OH)D deficiency and PSG-derived sleep parameters, we were able to efficiently and precisely measure the independent associations between the studied factors. However, our conclusions have some limitations. The study design does not allow any inference about causality between lower 25(OH)D and sleep parameters. Additionally, other potential confounders in the studied associations could not be measured and included in the analyses. As an example, although we included indirect measurements of sunlight exposure, such as seasonality and inactive lifestyle status, more reliable methods of outdoor activities and sunlight exposition could not be used. Other factors commonly related to 25(OH)D deficiency and sleep disorders, such as depression, pain and 25(OH)D dietary intake, were not assessed in this study. \[[@pone.0180901.ref009]\] Moreover, the current lack of a consensus regarding the appropriate cut-off levels for 25(OH)D deficiency led us to consider the US Endocrine Society Clinical Practice Guideline definition for vitamin D insufficiency (25(OH)D\<30 ng/mL) in our study. \[[@pone.0180901.ref023]\] In fact, it has been suggested that individuals with 25(OH)D\<30 ng/mL are at risk for vitamin D deficiency or in suboptimal vitamin D levels. However, more studies are expected to define the adequate vitamin D levels related to the reduction of several clinical outcomes, including those directly or indirectly associated to sleep disorders.

Despite the fact that PSGs were performed respecting the habitual bedtime of the participants, data interpretation was limited by the single night PSG recordings and the consequent problems derived from potential poor compliance or lack of habituation during the sleep study. Although we have performed a statistical analysis looking at the effects of sleep efficiency on the risk of vitamin D deficiency to reduce the source of bias related to a single night measurement effect, little is known about the presence of participants with a specific short sleep duration phenotype in our sample, which might aid to define the underlying mechanisms involved in the association between 25(OH)D levels and short sleep duration. Nevertheless, short sleep duration, regardless of its cause, seems to be an independent risk factor for main clinical outcomes, including obesity, type 2 diabetes, hypertension, and cardiovascular disease. \[[@pone.0180901.ref038]\]

Conclusions {#sec014}
===========

To our knowledge, this is the first study to demonstrate that moderate to severe OSA and objective short sleep duration are independently associated with the risk of 25(OH)D deficiency in an adult sample population. An age-related mechanism related to vitamin D serum levels and metabolism, as well as the higher prevalence of sleep complains and disorders in older adults, may support our findings. As both OSA and sleep curtailment as well as 25(OH)D deficiency are increasingly frequent and found to be linked to some of the most prevalent chronic diseases worldwide, implementing strategies to reduce the impact of these conditions on morbimortality are welcome. Therefore, future studies, mainly clinical trials, testing the effects of sleep-related interventions on serum 25(OH)D status or vice-versa are expected.
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